{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T22:45:33Z","timestamp":1784155533299,"version":"3.55.0"},"reference-count":65,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,2,12]],"date-time":"2024-02-12T00:00:00Z","timestamp":1707696000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2024,5]]},"DOI":"10.1016\/j.clml.2024.01.005","type":"journal-article","created":{"date-parts":[[2024,1,12]],"date-time":"2024-01-12T16:04:54Z","timestamp":1705075494000},"page":"285-297","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"title":["A Review of the Therapeutic Role of Bosutinib in Chronic Myeloid Leukemia"],"prefix":"10.1016","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1908-3307","authenticated-orcid":false,"given":"Hagop M.","family":"Kantarjian","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elias J.","family":"Jabbour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey H.","family":"Lipton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fausto","family":"Castagnetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tim H.","family":"Br\u00fcmmendorf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clml.2024.01.005_bib0001","unstructured":"US Food & Drug Administration. FDA grants accelerated approval to bosutinib for treatment of newly-diagnosed PH+ CML. https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-grants-accelerated-approval-bosutinib-treatment-newly-diagnosed-ph-cml. Accessed 24 October 2023."},{"key":"10.1016\/j.clml.2024.01.005_bib0002","unstructured":"European Medicines Agency. Bosulif (bosutinib) product information. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/bosulif. Accessed 23 October 2023."},{"issue":"17","key":"10.1016\/j.clml.2024.01.005_bib0003","doi-asserted-by":"crossref","first-page":"4567","DOI":"10.1182\/blood-2011-05-355594","article-title":"Safety and efficacy of bosutinib (SKI-606) in chronic phase Philadelphia chromosome-positive chronic myeloid leukemia patients with resistance or intolerance to imatinib","volume":"118","author":"Cortes","year":"2011","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.clml.2024.01.005_bib0004","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1002\/ajh.24536","article-title":"Long-term bosutinib for chronic phase chronic myeloid leukemia after failure of imatinib plus dasatinib and\/or nilotinib","volume":"91","author":"Cortes","year":"2016","journal-title":"Am J Hematol"},{"issue":"suppl 1","key":"10.1016\/j.clml.2024.01.005_bib0005","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1182\/blood-2021-150352","article-title":"Efficacy and safety of bosutinib in previously treated patients with chronic myeloid leukemia: final results from the BYOND trial","volume":"138","author":"Gambacorti-Passerini","year":"2021","journal-title":"Blood"},{"issue":"suppl 15","key":"10.1016\/j.clml.2024.01.005_bib0006","doi-asserted-by":"crossref","first-page":"7009","DOI":"10.1200\/JCO.2021.39.15_suppl.7009","article-title":"Second-line bosutinib (BOS) for patients (pts) with chronic phase (CP) chronic myeloid leukemia (CML): final 10-year results of a phase 1\/2 study","volume":"39","author":"Gambacorti-Passerini","year":"2021","journal-title":"J Clin Oncol"},{"issue":"8","key":"10.1016\/j.clml.2024.01.005_bib0007","doi-asserted-by":"crossref","first-page":"2125","DOI":"10.1038\/s41375-020-0915-9","article-title":"Bosutinib for pretreated patients with chronic phase chronic myeloid leukemia: primary results of the phase 4 BYOND study","volume":"34","author":"Hochhaus","year":"2020","journal-title":"Leukemia"},{"issue":"15","key":"10.1016\/j.clml.2024.01.005_bib0008","doi-asserted-by":"crossref","first-page":"3403","DOI":"10.1182\/blood-2011-11-390120","article-title":"Bosutinib is active in chronic phase chronic myeloid leukemia after imatinib and dasatinib and\/or nilotinib therapy failure","volume":"119","author":"Khoury","year":"2012","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.clml.2024.01.005_bib0009","doi-asserted-by":"crossref","first-page":"1825","DOI":"10.1038\/s41375-022-01589-y","article-title":"Bosutinib versus imatinib for newly diagnosed chronic phase chronic myeloid leukemia: final results from the BFORE trial","volume":"36","author":"Brummendorf","year":"2022","journal-title":"Leukemia"},{"issue":"1","key":"10.1016\/j.clml.2024.01.005_bib0010","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1038\/s41408-023-00823-9","article-title":"Management of chronic myeloid leukemia in 2023 : common ground and common sense","volume":"13","author":"Senapati","year":"2023","journal-title":"Blood Cancer J"},{"issue":"3","key":"10.1016\/j.clml.2024.01.005_bib0011","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1007\/s11899-018-0449-7","article-title":"Tyrosine kinase inhibitors in the treatment of chronic-phase CML: strategies for frontline decision-making","volume":"13","author":"Kennedy","year":"2018","journal-title":"Curr Hematol Malig Rep"},{"key":"10.1016\/j.clml.2024.01.005_bib0012","doi-asserted-by":"crossref","DOI":"10.1016\/j.blre.2021.100825","article-title":"Chronic myeloid leukemia: modern therapies, current challenges and future directions","volume":"49","author":"Osman","year":"2021","journal-title":"Blood Rev"},{"issue":"1","key":"10.1016\/j.clml.2024.01.005_bib0013","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/s12185-022-03446-1","article-title":"Guidelines for the treatment of chronic myeloid leukemia from the NCCN and ELN: differences and similarities","volume":"117","author":"Narli Ozdemir","year":"2023","journal-title":"Int J Hematol"},{"issue":"4","key":"10.1016\/j.clml.2024.01.005_bib0014","doi-asserted-by":"crossref","first-page":"2329","DOI":"10.1182\/blood-2007-05-092056","article-title":"Effective and selective inhibition of chronic myeloid leukemia primitive hematopoietic progenitors by the dual Src\/Abl kinase inhibitor SKI-606","volume":"111","author":"Konig","year":"2008","journal-title":"Blood"},{"issue":"23","key":"10.1016\/j.clml.2024.01.005_bib0015","doi-asserted-by":"crossref","first-page":"11314","DOI":"10.1158\/0008-5472.CAN-06-1199","article-title":"In vitro and in vivo activity of SKI-606, a novel Src-Abl inhibitor, against imatinib-resistant Bcr-Abl+ neoplastic cells","volume":"66","author":"Puttini","year":"2006","journal-title":"Cancer Res"},{"issue":"3","key":"10.1016\/j.clml.2024.01.005_bib0016","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1038\/leu.2008.334","article-title":"Global target profile of the kinase inhibitor bosutinib in primary chronic myeloid leukemia cells","volume":"23","author":"Remsing Rix","year":"2009","journal-title":"Leukemia"},{"issue":"3","key":"10.1016\/j.clml.2024.01.005_bib0017","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1200\/JCO.2017.74.7162","article-title":"Bosutinib versus imatinib for newly diagnosed chronic myeloid leukemia: results from the randomized BFORE trial","volume":"36","author":"Cortes","year":"2018","journal-title":"J Clin Oncol"},{"issue":"28","key":"10.1016\/j.clml.2024.01.005_bib0018","doi-asserted-by":"crossref","first-page":"3486","DOI":"10.1200\/JCO.2011.38.7522","article-title":"Bosutinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: results from the BELA trial","volume":"30","author":"Cortes","year":"2012","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.clml.2024.01.005_bib0019","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1111\/bjh.13108","article-title":"Bosutinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukaemia: results from the 24-month follow-up of the BELA trial","volume":"168","author":"Brummendorf","year":"2015","journal-title":"Br J Haematol"},{"issue":"7","key":"10.1016\/j.clml.2024.01.005_bib0020","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1002\/ajh.26550","article-title":"Treatment-free remission in patients with chronic myeloid leukemia following the discontinuation of tyrosine kinase inhibitors","volume":"97","author":"Haddad","year":"2022","journal-title":"Am J Hematol"},{"issue":"5","key":"10.1016\/j.clml.2024.01.005_bib0021","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1038\/leu.2016.5","article-title":"Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial","volume":"30","author":"Hochhaus","year":"2016","journal-title":"Leukemia"},{"issue":"7","key":"10.1016\/j.clml.2024.01.005_bib0022","doi-asserted-by":"crossref","first-page":"1825","DOI":"10.1038\/s41375-022-01589-y","article-title":"Bosutinib versus imatinib for newly diagnosed chronic phase chronic myeloid leukemia: final results from the BFORE trial","volume":"36","author":"Br\u00fcmmendorf","year":"2022","journal-title":"Leukemia"},{"issue":"12","key":"10.1016\/j.clml.2024.01.005_bib0023","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.1182\/blood-2016-09-696013","article-title":"The chronic myeloid leukemia stem cell: stemming the tide of persistence","volume":"129","author":"Holyoake","year":"2017","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.clml.2024.01.005_bib0024","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1038\/s41375-020-0776-2","article-title":"European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia","volume":"34","author":"Hochhaus","year":"2020","journal-title":"Leukemia"},{"issue":"suppl 4","key":"10.1016\/j.clml.2024.01.005_bib0025","doi-asserted-by":"crossref","first-page":"iv41","DOI":"10.1093\/annonc\/mdx219","article-title":"Chronic myeloid leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"28","author":"Hochhaus","year":"2017","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clml.2024.01.005_bib0026","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1097\/01.HS9.0000845676.81208.c2","article-title":"P698: Bosutinib dose optimization in the second-line treatment of elderly CML patients: extended 3-year follow-up and final results of the BEST study","volume":"6","author":"Castagnetti","year":"2022","journal-title":"HemaSphere"},{"issue":"21","key":"10.1016\/j.clml.2024.01.005_bib0027","doi-asserted-by":"crossref","first-page":"2031","DOI":"10.1182\/blood.2020009984","article-title":"A phase 3, open-label, randomized study of asciminib, a STAMP inhibitor, vs bosutinib in CML after 2 or more prior TKIs","volume":"138","author":"Rea","year":"2021","journal-title":"Blood"},{"issue":"16 suppl","key":"10.1016\/j.clml.2024.01.005_bib0028","doi-asserted-by":"crossref","first-page":"e19055","DOI":"10.1200\/JCO.2022.40.16_suppl.e19055","article-title":"Efficacy and safety of bosutinib in later-line patients (pts) with chronic myeloid leukemia (CML): a sub-analysis from the phase 4 BYOND trial","volume":"40","author":"Gambacorti-Passerini","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2024.01.005_bib0029","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.ejca.2019.08.002","article-title":"Clinical efficacy of the optimal biological dose in early-phase trials of anti-cancer targeted therapies","volume":"120","author":"Corbaux","year":"2019","journal-title":"Eur J Cancer"},{"issue":"6","key":"10.1016\/j.clml.2024.01.005_bib0030","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1158\/1078-0432.CCR-15-1295","article-title":"Optimal dosing for targeted therapies in oncology: drug development cases leading by example","volume":"22","author":"Sachs","year":"2016","journal-title":"Clin Cancer Res"},{"issue":"15","key":"10.1016\/j.clml.2024.01.005_bib0031","doi-asserted-by":"crossref","first-page":"1620","DOI":"10.1200\/JCO.2013.53.0204","article-title":"Oral anticancer drugs: how limited dosing options and dose reductions may affect outcomes in comparative trials and efficacy in patients","volume":"32","author":"Prasad","year":"2014","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.clml.2024.01.005_bib0032","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1186\/s13045-018-0685-2","article-title":"Management of adverse events associated with bosutinib treatment of chronic-phase chronic myeloid leukemia: expert panel review","volume":"11","author":"Cortes","year":"2018","journal-title":"J Hematol Oncol"},{"issue":"10","key":"10.1016\/j.clml.2024.01.005_bib0033","doi-asserted-by":"crossref","first-page":"2741","DOI":"10.1007\/s00277-023-05394-0","article-title":"Step-in dosing of bosutinib in pts with chronic phase chronic myeloid leukemia (CML) after second-generation tyrosine kinase inhibitor (TKI) therapy: results of the Bosutinib Dose Optimization (BODO) study","volume":"102","author":"Isfort","year":"2023","journal-title":"Ann Hematol"},{"key":"10.1016\/j.clml.2024.01.005_bib0034","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/s40164-018-0101-1","article-title":"Correlation of plasma concentration and adverse effects of bosutinib: standard dose or dose-escalation regimens of bosutinib treatment for patients with chronic myeloid leukemia","volume":"7","author":"Mita","year":"2018","journal-title":"Exp Hematol Oncol"},{"key":"10.1016\/j.clml.2024.01.005_bib0035","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1182\/blood-2019-127514","article-title":"Dose optimization in elderly CML patients treated with bosutinib after intolerance or failure of first-line tyrosine kinase inhibitors","volume":"134","author":"Castagnetti","year":"2019","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.clml.2024.01.005_bib0036","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1002\/hon.2851","article-title":"Bosutinib in the real-life treatment of chronic myeloid leukemia patients aged >65 years resistant\/intolerant to previous tyrosine-kinase inhibitors","volume":"39","author":"Latagliata","year":"2021","journal-title":"Hematol Oncol"},{"issue":"7","key":"10.1016\/j.clml.2024.01.005_bib0037","doi-asserted-by":"crossref","first-page":"e310","DOI":"10.1016\/S2352-3026(17)30066-2","article-title":"De-escalation of tyrosine kinase inhibitor dose in patients with chronic myeloid leukaemia with stable major molecular response (DESTINY): an interim analysis of a non-randomised, phase 2 trial","volume":"4","author":"Clark","year":"2017","journal-title":"Lancet Haematol"},{"issue":"6","key":"10.1016\/j.clml.2024.01.005_bib0038","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1038\/leu.2015.73","article-title":"The EUTOS population-based registry: incidence and clinical characteristics of 2904 CML patients in 20 European countries","volume":"29","author":"Hoffmann","year":"2015","journal-title":"Leukemia"},{"issue":"12","key":"10.1016\/j.clml.2024.01.005_bib0039","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1016\/j.clml.2015.09.008","article-title":"Use of real-world claim databases to assess prevalence of comorbid conditions relevant to the treatment of chronic myelogenous leukemia based on National Comprehensive Network Treatment Guidelines","volume":"15","author":"Jabbour","year":"2015","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.clml.2024.01.005_bib0040","doi-asserted-by":"crossref","DOI":"10.1016\/j.blre.2022.100968","article-title":"Long-term safety review of tyrosine kinase inhibitors in chronic myeloid leukemia : What to look for when treatment-free remission is not an option","volume":"56","author":"Lipton","year":"2022","journal-title":"Blood Rev"},{"issue":"1","key":"10.1016\/j.clml.2024.01.005_bib0041","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1182\/blood-2015-01-617993","article-title":"Impact of comorbidities on overall survival in patients with chronic myeloid leukemia: results of the randomized CML study IV","volume":"126","author":"Saussele","year":"2015","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.clml.2024.01.005_bib0042","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1182\/hematology.2020006911","article-title":"How to manage CML patients with comorbidities","volume":"2020","author":"Cortes","year":"2020","journal-title":"Hematology Am Soc Hematol Educ Program"},{"issue":"1","key":"10.1016\/j.clml.2024.01.005_bib0043","doi-asserted-by":"crossref","first-page":"IJH38","DOI":"10.2217\/ijh-2021-0010","article-title":"The effect of comorbidities on the choice of tyrosine kinase inhibitors in patients with chronic myeloid leukemia","volume":"11","author":"Saydam","year":"2022","journal-title":"Int J Hematol Oncol"},{"issue":"6","key":"10.1016\/j.clml.2024.01.005_bib0044","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1111\/ejh.13608","article-title":"Long-term cardiac, vascular, hypertension, and effusion safety of bosutinib in patients with philadelphia chromosome-positive leukemia resistant or intolerant to prior therapy","volume":"106","author":"Cortes","year":"2021","journal-title":"Eur J Haematol"},{"issue":"2","key":"10.1016\/j.clml.2024.01.005_bib0045","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1111\/bjh.16971","article-title":"A British Society for Haematology Guideline on the diagnosis and management of chronic myeloid leukaemia","volume":"191","author":"Smith","year":"2020","journal-title":"Br J Haematol"},{"issue":"1","key":"10.1016\/j.clml.2024.01.005_bib0046","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1111\/ejh.13775","article-title":"A retrospective observational research study to describe the real-world use of bosutinib in patients with chronic myeloid leukemia in the United Kingdom and the Netherlands","volume":"109","author":"Claudiani","year":"2022","journal-title":"Eur J Haematol"},{"issue":"1","key":"10.1016\/j.clml.2024.01.005_bib0047","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1038\/s41375-023-02080-y","article-title":"Impact of age and comorbidities on the efficacy and tolerability of bosutinib in previously treated patients with chronic myeloid leukemia: 3 results from the phase 4 BYOND study","volume":"38","author":"Rosti","year":"2023","journal-title":"Leukemia"},{"issue":"5","key":"10.1016\/j.clml.2024.01.005_bib0048","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1016\/S1470-2045(16)00080-2","article-title":"Ponatinib versus imatinib for newly diagnosed chronic myeloid leukaemia: an international, randomised, open-label, phase 3 trial","volume":"17","author":"Lipton","year":"2016","journal-title":"Lancet Oncol"},{"issue":"6","key":"10.1016\/j.clml.2024.01.005_bib0049","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1002\/ajh.25792","article-title":"Chronic myeloid leukemia: 2020 update on diagnosis, therapy and monitoring","volume":"95","author":"Jabbour","year":"2020","journal-title":"Am J Hematol"},{"issue":"3","key":"10.1016\/j.clml.2024.01.005_bib0050","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1093\/annonc\/mdy019","article-title":"Practical management of toxicities associated with bosutinib in patients with philadelphia chromosome-positive chronic myeloid leukemia","volume":"29","author":"Khoury","year":"2018","journal-title":"Ann Oncol"},{"issue":"8","key":"10.1016\/j.clml.2024.01.005_bib0051","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2022-071456","article-title":"Fluid retention-associated adverse events in patients treated with BCR::ABL1 inhibitors based on FDA Adverse Event Reporting System (FAERS): a retrospective pharmacovigilance study","volume":"13","author":"Huang","year":"2023","journal-title":"BMJ Open"},{"issue":"10","key":"10.1016\/j.clml.2024.01.005_bib0052","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1002\/ajh.23788","article-title":"Safety of bosutinib versus imatinib in the phase 3 BELA trial in newly diagnosed chronic phase chronic myeloid leukemia","volume":"89","author":"Gambacorti-Passerini","year":"2014","journal-title":"Am J Hematol"},{"issue":"suppl 1","key":"10.1016\/j.clml.2024.01.005_bib0053","doi-asserted-by":"crossref","first-page":"1484","DOI":"10.1182\/blood-2021-152017","article-title":"Incidence of pleural effusion with dasatinib and the effect of switching therapy to bosutinib in patients with chronic phase CML","volume":"138","author":"Jain","year":"2021","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.clml.2024.01.005_bib0054","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1177\/10781552221114070","article-title":"Bosutinib-induced massive pleural effusion: cross-intolerance with all tyrosine kinase inhibitors","volume":"29","author":"Aslan","year":"2023","journal-title":"J Oncol Pharm Pract"},{"issue":"4","key":"10.1016\/j.clml.2024.01.005_bib0055","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/j.blre.2018.01.004","article-title":"Cardiovascular, pulmonary, and metabolic toxicities complicating tyrosine kinase inhibitor therapy in chronic myeloid leukemia: strategies for monitoring, detecting, and managing","volume":"32","author":"Medeiros","year":"2018","journal-title":"Blood Rev"},{"issue":"8","key":"10.1016\/j.clml.2024.01.005_bib0056","doi-asserted-by":"crossref","first-page":"1648","DOI":"10.1038\/leu.2016.104","article-title":"European LeukemiaNet recommendations for the management and avoidance of adverse events of treatment in chronic myeloid leukaemia","volume":"30","author":"Steegmann","year":"2016","journal-title":"Leukemia"},{"issue":"2","key":"10.1016\/j.clml.2024.01.005_bib0057","doi-asserted-by":"crossref","first-page":"4395","DOI":"10.2217\/fon-2019-0555","article-title":"The role of bosutinib in the treatment of chronic myeloid leukemia","volume":"16","author":"Gambacorti-Passerini","year":"2020","journal-title":"Future Oncol"},{"issue":"1","key":"10.1016\/j.clml.2024.01.005_bib0058","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1007\/s00280-012-1987-7","article-title":"Evaluation of the pharmacokinetics and safety of bosutinib in patients with chronic hepatic impairment and matched healthy subjects","volume":"71","author":"Abbas","year":"2013","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.clml.2024.01.005_bib0059","unstructured":"Pfizer Inc. Bosulif (bosutinib) dosing and administration. https:\/\/bosulif.pfizerpro.com\/dosing\/dosing-and-administration. Accessed 25 October 2023."},{"issue":"1","key":"10.1016\/j.clml.2024.01.005_bib0060","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1080\/17474086.2017.1262758","article-title":"How could patient reported outcomes improve patient management in chronic myeloid leukemia?","volume":"10","author":"De Marchi","year":"2017","journal-title":"Expert Rev Hematol"},{"issue":"6","key":"10.1016\/j.clml.2024.01.005_bib0061","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1007\/s00432-019-02894-3","article-title":"Patient-reported outcomes in the phase 3 BFORE trial of bosutinib versus imatinib for newly diagnosed chronic phase chronic myeloid leukemia","volume":"145","author":"Cortes","year":"2019","journal-title":"J Cancer Res Clin Oncol"},{"issue":"3","key":"10.1016\/j.clml.2024.01.005_bib0062","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1002\/cncr.31082","article-title":"Long-term patient-reported outcomes from an open-label safety and efficacy study of bosutinib in Philadelphia chromosome-positive chronic myeloid leukemia patients resistant or intolerant to prior therapy","volume":"124","author":"Kantarjian","year":"2018","journal-title":"Cancer"},{"issue":"4","key":"10.1016\/j.clml.2024.01.005_bib0063","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1016\/j.leukres.2011.10.011","article-title":"Health-related quality of life of bosutinib (SKI-606) in imatinib-resistant or imatinib-intolerant chronic phase chronic myeloid leukemia","volume":"36","author":"Trask","year":"2012","journal-title":"Leuk Res"},{"issue":"8","key":"10.1016\/j.clml.2024.01.005_bib0064","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1185\/03007995.2016.1174108","article-title":"Health-related quality of life during bosutinib (SKI-606) therapy in patients with advanced chronic myeloid leukemia after imatinib failure","volume":"32","author":"Whiteley","year":"2016","journal-title":"Curr Med Res Opin"},{"issue":"6","key":"10.1016\/j.clml.2024.01.005_bib0065","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1007\/s00277-020-04018-1","article-title":"Relationship between molecular response and quality of life with bosutinib or imatinib for chronic myeloid leukemia","volume":"99","author":"Brummendorf","year":"2020","journal-title":"Ann Hematol"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265024000223?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265024000223?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,10,18]],"date-time":"2024-10-18T04:42:22Z","timestamp":1729226542000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265024000223"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5]]},"references-count":65,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2024,5]]}},"alternative-id":["S2152265024000223"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2024.01.005","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2024,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A Review of the Therapeutic Role of Bosutinib in Chronic Myeloid Leukemia","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2024.01.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}